Top Companies in Mice Model

The global mice models market is projected to reach USD 2.74 billion by 2030 from USD 1.70 billion in 2025, at a CAGR of 10.0% during the forecast period.

The global mice models market is consolidated, featuring companies like Charles River Laboratories (US), Inotiv (US), THE JACKSON LABORATORY (US), JSR Corporation (Japan), Biocytogen (China), Trans Genic Inc. (Japan) Harbour BioMed (China), genOway (France), GemPharmatech (China), Cyagen (US), Ozgene Pty Ltd (Australia), and Taconic Biosciences, Inc. (US), among others. These market players have implemented several strategies, including product/service launches & approvals, acquisitions, agreements, collaborations, and expansions, to enhance their positions in the market.

To know about the assumptions considered for the study download the pdf brochure

Charles River Laboratories (US)

Charles River Laboratories is a key player in the mice models market, offering over 150 specialized strains, including immunodeficient, humanized, and genetically engineered models. Its integrated services—from model procurement and colony management to study design—cater to pharmaceutical, biotech, CROs, academic, and government clients. The company’s extensive global production network, with AAALAC-accredited facilities across North America, Europe, and the Asia Pacific, ensures fast delivery and high-quality standards. Recent expansions, such as the CRADL vivarium in Somerville (2024) and the advanced imaging-equipped Kuopio facility (2025), further strengthen its in vivo capabilities. Strategic initiatives like licensing the NCG Mouse line from GemPharmaTech and the USD 200 million Alternative Methods Advancement Project (AMAP) highlight its commitment to innovation and regulatory alignment, especially with the FDA’s 2025 push for non-animal testing.

THE JACKSON LABORATORY (US):

The Jackson Laboratory (JAX) is a prominent nonprofit biomedical research institution recognized for its deep expertise in developing transgenic and targeted mutant mouse models. Its extensive portfolio is supported by strong intellectual property and advanced genetic engineering technologies, making it a key contributor to preclinical drug research. In December 2023, JAX was granted a US patent for a novel method to assess immunomodulatory drug toxicity, underscoring its translational science innovation. Strategic collaborations with organizations like Charles River Laboratories (US), Ozgene Pty Ltd (Australia), and Unravel Biosciences, Inc. (US) have expanded its global distribution and research impact. JAX continues to reinvest significantly in R&D, reflecting its long-term commitment to advancing biomedical science.

Inotiv (US):

Inotiv is a key player in the mice models market, known for its broad portfolio of research strains, including genetically engineered, immunodeficient, and standard inbred models. Strategic acquisitions such as Histion, Orient BioResource Center, Integrated Laboratory Systems, and Robinson Services have significantly expanded its capabilities across surgical models, rodent supply, toxicology services, and rabbit breeding. Inotiv operates multiple production sites across North America and Europe, with barrier rooms and isolator suites to ensure rapid and high-quality model delivery. The company’s advanced facilities, including the expanded lab center in Rockville, MD, support cutting-edge breeding and colony management.

Related Reports:

Mice Model Market by Model Type (Inbred, Outbred, Hybrid), Service (Breeding, Rederivation), Application (Personalized Medicine), Technology (Microinjection, CRISPR/Cas9), Therapeutic Area (Oncology, Neurology), End User (CROs) - Global Forecast to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets Inc.
1615 South Congress Ave.
Suite 103,
Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com